Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands.

Gregori L, Lambert BC, Gurgel PV, Gheorghiu L, Edwardson P, Lathrop JT, Macauley C, Carbonell RG, Burton SJ, Hammond D, Rohwer RG.

Transfusion. 2006 Jul;46(7):1152-61.

PMID:
16836562
2.

Removal of exogenous prion infectivity in leukoreduced red blood cells unit by a specific filter designed for human transfusion.

Lescoutra-Etchegaray N, Sumian C, Culeux A, Durand V, Gurgel PV, Deslys JP, Comoy EE.

Transfusion. 2014 Apr;54(4):1037-45. doi: 10.1111/trf.12420.

PMID:
24117735
3.

Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins.

Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG.

Lancet. 2006 Dec 23;368(9554):2226-30.

PMID:
17189034
5.

A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.

Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr.

Transfusion. 2001 Apr;41(4):449-55. Erratum in: Transfusion 2001 Aug;41(8):1079.

PMID:
11316893
6.

Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.

Sowemimo-Coker S, Kascsak R, Kim A, Andrade F, Pesci S, Kascsak R, Meeker C, Carp R, Brown P.

Transfusion. 2005 Dec;45(12):1839-44. Erratum in: Transfusion. 2006 Feb;46(2):313.

PMID:
16371036
7.

Assessment of prion reduction filters in decreasing infectivity of ultracentrifuged 263K scrapie-infected brain homogenates in "spiked" human blood and red blood cells.

Cardone F, Sowemimo-Coker S, Abdel-Haq H, Sbriccoli M, Graziano S, Valanzano A, Berardi VA, Galeno R, Puopolo M, Pocchiari M.

Transfusion. 2014 Apr;54(4):990-5. doi: 10.1111/trf.12369.

PMID:
23915063
8.

Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.

Sowemimo-Coker SO, Pesci S, Andrade F, Kim A, Kascsak RB, Kascsak RJ, Meeker C, Carp R.

Vox Sang. 2006 May;90(4):265-75.

PMID:
16635068
9.

A prion reduction filter does not completely remove endogenous prion infectivity from sheep blood.

McCutcheon S, Alejo Blanco AR, Tan BC, González L, Martin S, Mallinson G, Appleford NE, Turner ML, Manson JC, Houston EF.

Transfusion. 2015 Sep;55(9):2123-33. doi: 10.1111/trf.13145.

PMID:
26032915
10.

A sensitive and quantitative assay for normal PrP in plasma.

Gregori L, Gray BN, Rose E, Spinner DS, Kascsak RJ, Rohwer RG.

J Virol Methods. 2008 May;149(2):251-9. doi: 10.1016/j.jviromet.2008.01.028.

PMID:
18339433
11.

Prion protein and the red cell.

Anstee DJ.

Curr Opin Hematol. 2007 May;14(3):210-4. Review.

PMID:
17414209
12.

Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies.

Heger A, Bailey A, Neisser-Svae A, Ertl M, Römisch J, Svae TE.

Vox Sang. 2012 May;102(4):294-301. doi: 10.1111/j.1423-0410.2011.01563.x.

PMID:
22070802
13.

Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.

Diez JM, Caballero S, Belda FJ, Otegui M, Gajardo R, Jorquera JI.

Haemophilia. 2009 Nov;15(6):1249-57. doi: 10.1111/j.1365-2516.2009.02067.x.

PMID:
19563480
14.

The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy.

Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN.

Transfusion. 1998 Sep;38(9):810-6.

PMID:
9738619
15.

Comparative studies on the thermostability of five strains of transmissible-spongiform-encephalopathy agent.

Fernie K, Steele PJ, Taylor DM, Somerville RA.

Biotechnol Appl Biochem. 2007 Aug;47(Pt 4):175-83.

PMID:
17331068
16.
17.

Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation.

Cancelas JA, Rugg N, Pratt PG, Worsham DN, Pehta JC, Banks K, Davenport RD, Judd WJ.

Transfusion. 2011 Oct;51(10):2228-36. doi: 10.1111/j.1537-2995.2011.03133.x.

PMID:
21492178
18.

Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood.

Gregori L, Yang H, Anderson S.

Transfusion. 2011 Dec;51(12):2596-602. doi: 10.1111/j.1537-2995.2011.03199.x.

PMID:
21645006
19.

Evaluation of removal of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture-based infectivity assay.

Sowemimo-Coker SO, Demczyk CA, Andrade F, Baker CA.

Transfusion. 2010 May;50(5):980-8. doi: 10.1111/j.1537-2995.2009.02525.x.

PMID:
20003057
20.

Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy.

Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P.

Transfusion. 2003 Dec;43(12):1687-94.

PMID:
14641865
Items per page

Supplemental Content

Support Center